Publications by authors named "Denise Wrobel"
Introduction: Prognosis of patients diagnosed with HER2+ early breast cancer (eBC) has substantially improved, but distant recurrences impacting quality of life and survival still occur. One treatment option for extended adjuvant treatment of patients with HER2+/HR+ eBC is neratinib, available in Europe for patients who completed adjuvant trastuzumab-based therapy within 1 year. The ELEANOR study is investigating the real-world use of neratinib in Germany, Austria, and Switzerland.
View Article and Find Full Text PDFArticle Synopsis
- * The BREVITY clinical trial aims to confirm earlier studies and has reported findings from its training phase, establishing RNA disruption index (RDI) cut points for predicting patient outcomes.
- * In the training set, higher RDI values were associated with responders achieving a pathologic complete response, while an RDI value of ≤3.7 strongly predicted a lack of response, indicating potential for optimizing treatment based on RNA disruption assessments.